EP2972320A4 - Imagerie par fluorescence de maladies inflammatoires - Google Patents

Imagerie par fluorescence de maladies inflammatoires

Info

Publication number
EP2972320A4
EP2972320A4 EP13877792.5A EP13877792A EP2972320A4 EP 2972320 A4 EP2972320 A4 EP 2972320A4 EP 13877792 A EP13877792 A EP 13877792A EP 2972320 A4 EP2972320 A4 EP 2972320A4
Authority
EP
European Patent Office
Prior art keywords
methods
inflammatory diseases
fluorescent compounds
ligands conjugated
imaging inflammatory
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP13877792.5A
Other languages
German (de)
English (en)
Other versions
EP2972320B1 (fr
EP2972320A1 (fr
Inventor
Philip S Low
Sumith A Kularatne
Lindsay E Kelderhouse
Sakkarapalayam M Mahalingam
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KELDERHOUSE, LINDSAY E.
KULARATNE, SUMITH A.
LOW, PHILIP S.
Purdue Research Foundation
Original Assignee
Purdue Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Purdue Research Foundation filed Critical Purdue Research Foundation
Publication of EP2972320A1 publication Critical patent/EP2972320A1/fr
Publication of EP2972320A4 publication Critical patent/EP2972320A4/fr
Application granted granted Critical
Publication of EP2972320B1 publication Critical patent/EP2972320B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0052—Small organic molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A61K49/0034—Indocyanine green, i.e. ICG, cardiogreen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
    • C07D475/04—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/64—Fluorescence; Phosphorescence
    • G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/64—Fluorescence; Phosphorescence
    • G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
    • G01N2021/6432—Quenching
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/64—Fluorescence; Phosphorescence
    • G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
    • G01N2021/6439—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes" with indicators, stains, dyes, tags, labels, marks
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2201/00—Features of devices classified in G01N21/00
    • G01N2201/06—Illumination; Optics
    • G01N2201/061—Sources
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Physiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Optics & Photonics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP13877792.5A 2013-03-15 2013-12-19 Imagerie par fluorescence de maladies inflammatoires Active EP2972320B1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361791921P 2013-03-15 2013-03-15
PCT/US2013/056629 WO2014149069A1 (fr) 2013-03-15 2013-08-26 Synthèse et composition de groupes de liaison d'acides aminés conjugués à des composés utilisés pour l'imagerie ciblée de tumeurs
US14/010,098 US9333270B2 (en) 2013-03-15 2013-08-26 Synthesis and composition of amino acid linking groups conjugated to compounds used for the targeted imaging of tumors
US14/046,916 US9254341B2 (en) 2013-03-15 2013-10-04 Methods of manufacture of pteroyl-amino acid-fluorescent dyes
PCT/US2013/076659 WO2014143309A1 (fr) 2013-03-15 2013-12-19 Imagerie par fluorescence de maladies inflammatoires

Publications (3)

Publication Number Publication Date
EP2972320A1 EP2972320A1 (fr) 2016-01-20
EP2972320A4 true EP2972320A4 (fr) 2016-10-26
EP2972320B1 EP2972320B1 (fr) 2019-10-23

Family

ID=51527878

Family Applications (3)

Application Number Title Priority Date Filing Date
EP13878809.6A Active EP2968335B1 (fr) 2013-03-15 2013-08-26 Synthèse et composition de groupes de liaison d'acides aminés conjugués à des composés utilisés pour l'imagerie ciblée de tumeurs
EP13878632.2A Active EP2968614B1 (fr) 2013-03-15 2013-10-04 Procédés de fabrication et de synthèse de groupes de liaison d'acide aminé conjugués à des composés utilisés pour l'imagerie ciblée de tumeurs
EP13877792.5A Active EP2972320B1 (fr) 2013-03-15 2013-12-19 Imagerie par fluorescence de maladies inflammatoires

Family Applications Before (2)

Application Number Title Priority Date Filing Date
EP13878809.6A Active EP2968335B1 (fr) 2013-03-15 2013-08-26 Synthèse et composition de groupes de liaison d'acides aminés conjugués à des composés utilisés pour l'imagerie ciblée de tumeurs
EP13878632.2A Active EP2968614B1 (fr) 2013-03-15 2013-10-04 Procédés de fabrication et de synthèse de groupes de liaison d'acide aminé conjugués à des composés utilisés pour l'imagerie ciblée de tumeurs

Country Status (13)

Country Link
US (7) US9333270B2 (fr)
EP (3) EP2968335B1 (fr)
JP (5) JP6192799B2 (fr)
CN (3) CN105228628B (fr)
AU (4) AU2013383382B2 (fr)
BR (1) BR112015022810B1 (fr)
CA (3) CA2903994C (fr)
EA (1) EA029738B1 (fr)
ES (1) ES2765896T3 (fr)
HK (1) HK1218257A1 (fr)
IL (3) IL240509B (fr)
MX (3) MX358184B (fr)
WO (3) WO2014149069A1 (fr)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0809442A2 (pt) 2007-03-27 2014-09-09 Radiomedix Inc Composições para terapia e formação de imagens direcionada
CA2843313C (fr) 2011-06-20 2018-02-13 Radiomedix Inc. Compositions, procedes de synthese et utilisation d'agents cibles sur les glucides
US20170232119A1 (en) * 2013-03-15 2017-08-17 Purdue Research Foundation Synthesis and composition of amino acid linking groups conjugated to compounds used for the targeted imaging of tumors
CA2903994C (fr) * 2013-03-15 2017-08-22 Philip S. Low Synthese et composition de groupes de liaison d'acides amines conjugues a des composes utilises pour l'imagerie ciblee de tumeurs
ES2860173T3 (es) * 2013-11-19 2021-10-04 Purdue Research Foundation Método de selección de pacientes para inflamación
US10280307B2 (en) 2014-11-05 2019-05-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Class of stable heptamethine cyanine fluorophores and biomedical applications thereof
JP6560766B2 (ja) 2015-05-12 2019-08-14 メディビーコン，インク． 目の血管系を評価するための組成物及び方法
FR3036622B1 (fr) * 2015-05-25 2017-05-19 Fluoptics Traceur fluorescent ciblant multivalent optimise.
FR3036621B1 (fr) * 2015-05-25 2017-05-19 Fluoptics Traceur fluorescent ciblant multivalent dans le proche infrarouge pour imagerie optique.
US9808538B2 (en) 2015-09-09 2017-11-07 On Target Laboratories, LLC PSMA-targeted NIR dyes and their uses
US10842887B2 (en) 2015-09-09 2020-11-24 On Target Laboratories, LLC PSMA-targeted NIR dyes and their uses
BR112018068142B1 (pt) * 2016-03-16 2023-02-14 On Target Laboratories, LLC Compostos ou sais farmaceuticamente aceitáveis dos mesmos e kit
US11555821B2 (en) 2016-03-16 2023-01-17 On Target Laboratories, Inc. CA IX-NIR dyes and their uses
EP3493855A4 (fr) 2016-08-02 2020-04-01 ISI Life Sciences, Inc. Méthode de détection de cellules cancéreuses.
EP3496762A1 (fr) 2016-08-11 2019-06-19 The U.S.A. as represented by the Secretary, Department of Health and Human Services Conjugués clivables par la lumière du proche infrarouge et précurseurs de conjugués
ES2944610T3 (es) * 2016-09-09 2023-06-22 On Target Laboratories Llc Colorantes NIR dirigidos a PSMA y sus usos
EP3509617A4 (fr) * 2016-09-09 2020-05-13 On Target Laboratories, LLC Imagerie nir ciblée sur le récepteur de cholécystokinine 2 et son utilisation
JP2019534286A (ja) * 2016-10-26 2019-11-28 カオ グループ、インク． 放射エネルギーによる崩壊の標的とされる癌結合性有色ペプチド
WO2018101473A1 (fr) * 2016-12-02 2018-06-07 国立大学法人東京大学 Composé, sonde fluorescente de visualisation de récepteur de folate, et applications de ceux-ci
CN116474108A (zh) 2016-12-14 2023-07-25 普渡研究基金会 成纤维细胞活化蛋白(fap)-靶向成像和治疗
US10753942B2 (en) 2017-05-15 2020-08-25 Indicator Systems International, Inc. Methods to detect remnant cancer cells
US10539567B2 (en) * 2017-05-15 2020-01-21 Indicator Systems International, Inc. Biopsy methods and devices
KR20200122338A (ko) * 2018-02-15 2020-10-27 칠드런스 내셔널 메디컬 센터 담도계 및 비뇨계의 형광 마커로서 사용하기 위한 헵타메틴 시아닌
CN108840815A (zh) * 2018-05-29 2018-11-20 苏州百源基因技术有限公司 一种荧光标记的氨基酸及其制备方法和用途
CN108727245B (zh) * 2018-07-02 2021-09-28 广州中医药大学(广州中医药研究院) 一种水杨酸类化合物及其制备方法和应用
KR102150415B1 (ko) * 2018-12-07 2020-09-01 원광대학교 산학협력단 암 표적용 화합물 및 이의 용도
JP7160694B2 (ja) 2019-01-08 2022-10-25 日立Ｇｅニュークリア・エナジー株式会社 流体接触部材及び流体接触部材の製造方法
US20200397245A1 (en) 2019-06-20 2020-12-24 Ethicon Llc Minimizing image sensor input/output in a pulsed fluorescence imaging system
US11716533B2 (en) * 2019-06-20 2023-08-01 Cilag Gmbh International Image synchronization without input clock and data transmission clock in a pulsed fluorescence imaging system
US11516387B2 (en) 2019-06-20 2022-11-29 Cilag Gmbh International Image synchronization without input clock and data transmission clock in a pulsed hyperspectral, fluorescence, and laser mapping imaging system
US11892403B2 (en) 2019-06-20 2024-02-06 Cilag Gmbh International Image synchronization without input clock and data transmission clock in a pulsed fluorescence imaging system
US11986160B2 (en) 2019-06-20 2024-05-21 Cllag GmbH International Image synchronization without input clock and data transmission clock in a pulsed hyperspectral imaging system
US20210353151A1 (en) * 2020-05-12 2021-11-18 On Target Laboratories, LLC Targeted fluorescent markers in combination with a flexible probe
CN112010862B (zh) * 2020-10-23 2021-03-30 南京诺源医疗器械有限公司 一种主动靶向叶酸受体近红外荧光分子及其制备方法
CN114014843B (zh) * 2021-11-17 2022-09-20 北京大学第一医院 一种psma靶向核素/荧光双模态配体和分子探针与应用
US11986540B2 (en) * 2022-02-23 2024-05-21 On Target Laboratories, LLC Compositions including pafolacianine for the identification of malignant lesions
CN114751907A (zh) * 2022-03-17 2022-07-15 南京诺源医疗器械有限公司 一种主动靶向叶酸受体近红外荧光分子及其制备方法和用途
CN115504984B (zh) * 2022-09-09 2023-07-25 南京诺源医疗器械有限公司 一种靶向α型叶酸受体的培美近红外荧光分子及其制备方法和应用
CN115490672B (zh) * 2022-09-30 2023-11-17 南华大学 一种兼具光热和光动力效应的光敏剂及其制备方法和应用
CN116621823B (zh) * 2023-07-06 2023-10-31 南京诺源医疗器械有限公司 诊断转移淋巴结近红外荧光示踪剂、合成方法及应用
CN118078219A (zh) * 2024-04-24 2024-05-28 新斗生物科技(苏州)有限公司 近红外荧光捕获系统、装置及应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4337339A (en) * 1979-04-30 1982-06-29 Baker Instruments Corp. Process for preparation of folic acid derivatives
US20060280688A1 (en) * 2000-09-19 2006-12-14 Li-Cor, Inc. Optical fluorescent imaging
WO2007139815A2 (fr) * 2006-05-23 2007-12-06 Purdue Research Foundation Procédé d'imagerie et de thérapie utilisant des cellules progénitrices
WO2010102238A1 (fr) * 2009-03-05 2010-09-10 Purdue Research Foundation Méthode d'imagerie précoce de l'athérosclérose

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5871711A (en) 1992-06-23 1999-02-16 Diatide, Inc. Radioactively-labeled somatostatin-derived peptides for imaging and therapeutic uses
US5716596A (en) 1992-06-23 1998-02-10 Diatide, Inc. Radioactively labeled somatostatin-derived peptides for imaging and therapeutic uses
DE19717904A1 (de) * 1997-04-23 1998-10-29 Diagnostikforschung Inst Säurelabile und enzymatisch spaltbare Farbstoffkonstrukte zur Diagnostik mit Nahinfrarotlicht und zur Therapie
JP2000095758A (ja) 1998-09-18 2000-04-04 Schering Ag 近赤外蛍光造影剤および蛍光造影方法
US7547721B1 (en) * 1998-09-18 2009-06-16 Bayer Schering Pharma Ag Near infrared fluorescent contrast agent and fluorescence imaging
TR200201567T2 (tr) 1999-12-15 2002-11-21 Schering Ag Kızılötesine yakın ışık bölgesinde aktif fluoresan kontrast maddesi ve fluoresans görüntü alma.
CZ304942B6 (cs) 2000-03-31 2015-02-04 Purdue Research Foundation Léčivo pro zvyšování specifické eliminace populace tumorových buněk a farmaceutický prostředek obsahující konjugát fosfát-FITC nebo fosfát-dinitrofenyl
ATE315066T1 (de) * 2000-09-19 2006-02-15 Li Cor Inc Cyaninfarbstoffe
EP1363920B1 (fr) 2001-02-07 2006-08-23 Beth Israel Deaconess Medical Center Ligands de la psma modifies et utilisation de ces derniers
KR20040015234A (ko) * 2001-05-02 2004-02-18 펄듀 리서치 파운데이션 대식세포 매개된 질환의 치료와 진단
EP1863816B1 (fr) * 2005-03-16 2014-06-25 Endocyte, Inc. Synthese et purification d'acide pteroique et des conjugues de celui-ci
JP5175723B2 (ja) * 2005-07-05 2013-04-03 パーデュー・リサーチ・ファウンデーション 単球介在性疾患を治療するための組成物の調製
US7547712B2 (en) * 2006-02-27 2009-06-16 Nabi Biopharmaceuticals Methods for decreasing the toxic effects of nicotine on fetuses in pregnant women
EP2087337A4 (fr) 2006-11-03 2010-09-08 Purdue Research Foundation Procédé de cytométrie en flux<i>ex vivo</i>et dispositif
US8168804B2 (en) * 2007-06-29 2012-05-01 Vanderbilt University Large stoke shift NIR dyes
DK2268317T3 (da) * 2008-03-14 2020-05-25 Visen Medical Inc Integrin-targeteringssubstanser og in vivo- og in vitro-billeddannelsesmetoder som anvender samme
CA2737496A1 (fr) 2008-09-17 2010-03-25 Endocyte, Inc. Conjugues d'antifolates liant le recepteur de folate
US8916137B2 (en) * 2008-11-07 2014-12-23 The General Hospital Corporation Monofunctional carbocyanine dyes for in vivo and in vitro imaging
CN101440282B (zh) * 2008-12-18 2012-06-27 中国药科大学 近红外荧光分子探针及其合成方法和用途
CN102459469A (zh) * 2009-04-17 2012-05-16 利康股份有限公司 用取代的花青染料进行荧光成像
US20130071321A1 (en) 2010-05-28 2013-03-21 Purdue Research Foundation Delivery of agents to inflamed tissues using folate-targeted liposomes
CN103313724A (zh) * 2010-09-06 2013-09-18 莫徳普罗有限公司 化合物和方法
EP2630196B1 (fr) * 2010-10-20 2017-09-06 Li-Cor, Inc. Colorants cyanine et leurs produits conjugués
US10080805B2 (en) 2012-02-24 2018-09-25 Purdue Research Foundation Cholecystokinin B receptor targeting for imaging and therapy
WO2013130776A1 (fr) * 2012-02-29 2013-09-06 Purdue Research Foundation Ligands de liaison au récepteur alpha de folates
CA2903994C (fr) * 2013-03-15 2017-08-22 Philip S. Low Synthese et composition de groupes de liaison d'acides amines conjugues a des composes utilises pour l'imagerie ciblee de tumeurs

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4337339A (en) * 1979-04-30 1982-06-29 Baker Instruments Corp. Process for preparation of folic acid derivatives
US20060280688A1 (en) * 2000-09-19 2006-12-14 Li-Cor, Inc. Optical fluorescent imaging
WO2007139815A2 (fr) * 2006-05-23 2007-12-06 Purdue Research Foundation Procédé d'imagerie et de thérapie utilisant des cellules progénitrices
WO2010102238A1 (fr) * 2009-03-05 2010-09-10 Purdue Research Foundation Méthode d'imagerie précoce de l'athérosclérose

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2014143309A1 *

Also Published As

Publication number Publication date
BR112015022810A2 (pt) 2020-04-28
EP2968335B1 (fr) 2019-03-27
AU2017203340B2 (en) 2019-05-02
IL240673B (en) 2019-06-30
CA2903727A1 (fr) 2014-09-25
HK1218257A1 (zh) 2017-02-10
WO2014143309A1 (fr) 2014-09-18
CN105120903A (zh) 2015-12-02
IL240673A0 (en) 2015-10-29
JP6192799B2 (ja) 2017-09-06
US9782497B2 (en) 2017-10-10
EP2968614A4 (fr) 2016-10-19
US9789208B2 (en) 2017-10-17
EP2968335A1 (fr) 2016-01-20
ES2765896T3 (es) 2020-06-11
US20170281800A9 (en) 2017-10-05
US9341629B2 (en) 2016-05-17
AU2013383382B2 (en) 2017-02-23
JP2017214425A (ja) 2017-12-07
IL240509A0 (en) 2015-10-29
JP2017149776A (ja) 2017-08-31
EA201591802A1 (ru) 2016-08-31
IL240828A (en) 2017-10-31
US9333270B2 (en) 2016-05-10
CA2902205A1 (fr) 2014-09-18
CN105492905A (zh) 2016-04-13
JP2016512240A (ja) 2016-04-25
CA2903994C (fr) 2017-08-22
EP2972320B1 (fr) 2019-10-23
US20140271482A1 (en) 2014-09-18
EP2968614B1 (fr) 2019-04-03
US9061057B2 (en) 2015-06-23
IL240828A0 (en) 2015-10-29
US9233175B2 (en) 2016-01-12
JP6270981B2 (ja) 2018-01-31
MX2015011830A (es) 2017-03-07
US20140271484A1 (en) 2014-09-18
US9254341B2 (en) 2016-02-09
EP2972320A1 (fr) 2016-01-20
CN105492905B (zh) 2018-12-07
EP2968614A1 (fr) 2016-01-20
CA2903994A1 (fr) 2014-09-25
CN105228628A (zh) 2016-01-06
EP2968335A4 (fr) 2016-10-26
US20160011199A1 (en) 2016-01-14
MX2015013223A (es) 2016-04-20
WO2014149073A1 (fr) 2014-09-25
US20140271476A1 (en) 2014-09-18
CA2903727C (fr) 2020-10-27
US20140275533A1 (en) 2014-09-18
AU2013383386A1 (en) 2015-09-03
CN105228628B (zh) 2019-10-18
BR112015022810B1 (pt) 2021-11-30
IL240509B (en) 2018-06-28
WO2014149069A1 (fr) 2014-09-25
AU2013381391A1 (en) 2015-08-27
JP2016512814A (ja) 2016-05-09
MX2015013219A (es) 2016-10-03
AU2017203340A1 (en) 2017-06-08
US20160375153A1 (en) 2016-12-29
MX358184B (es) 2018-08-08
JP2016512813A (ja) 2016-05-09
US20160339122A1 (en) 2016-11-24
AU2013383382A1 (en) 2015-09-03
EA029738B1 (ru) 2018-05-31

Similar Documents

Publication Publication Date Title
EP2972320A4 (fr) Imagerie par fluorescence de maladies inflammatoires
IL269227B (en) Solid forms of treprostinil
EP3919505C0 (fr) Utilisations des complexes d&#39;acide nucléique cas9
EP2970081A4 (fr) Sels de tréprostinil
EP3041578A4 (fr) Traitement de maladies inflammatoires par des matériaux carbonés
HK1224222A1 (zh) 製造苯並喹啉化合物的方法
GB201315851D0 (en) Antibodies to complex targets
EP2968321A4 (fr) Composés pour le traitement de maladies de fibrose
HK1218553A1 (zh) 抗激活素 化合物對受試者的施用
PL2984159T3 (pl) Wytwarzanie laktylanów bezpośrednio z oleju
EP2777425A4 (fr) Ensemble de butée inférieure de fermeture à glissière rapide à retirer
HK1214240A1 (zh) 用於製備酰亞胺基二硫酰化合物的方法
HK1214301A1 (zh) 治療 相關疾病的有機組合物
EP2859338A4 (fr) Quantification par rmn de tmao
IL243637A0 (en) PPAR-sparing compounds for the treatment of metabolic diseases
HK1213740A1 (zh) 製備抗癌症組合物的方法
IL244982B (en) Activation of hematopoietic progenitor cells by exposing them before transplantation to ligands that mediate cell death
BR112015024260A2 (pt) método de preparação de composto de acrilato
GB2516028B (en) Improved structure of shoe
HK1222400A1 (zh) 抗嗜酸細胞活化趨化因數抗體在治療炎症性腸病中的應用
HK1213554A1 (zh) 用於製備硼酸中間體的方法
HK1216150A1 (zh) 匹多莫德治療炎症性腸病的用途
PT2870968T (pt) Tratamento de doenças inflamatórias do intestino com clinoptilolite
TH1401005842A (th) แอนติบอดีต่อ siglec-15 ที่ดัดแปลง cdr
GB201306411D0 (en) Treatment of inflammatory conditions

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20150922

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20160926

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 49/00 20060101AFI20160920BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20180201

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Ref document number: 602013062132

Country of ref document: DE

Free format text: PREVIOUS MAIN CLASS: G01N0033500000

Ipc: A61K0049000000

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

RIC1 Information provided on ipc code assigned before grant

Ipc: C07D 475/04 20060101ALI20190415BHEP

Ipc: G01N 33/566 20060101ALI20190415BHEP

Ipc: A61P 37/00 20060101ALI20190415BHEP

Ipc: A61K 49/00 20060101AFI20190415BHEP

INTG Intention to grant announced

Effective date: 20190514

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: LOW, PHILIP S.

Owner name: KELDERHOUSE, LINDSAY E.

Owner name: KULARATNE, SUMITH A.

Owner name: PURDUE RESEARCH FOUNDATION

RIN1 Information on inventor provided before grant (corrected)

Inventor name: MAHALINGAM, SAKKARAPALAYAM, M

Inventor name: KELDERHOUSE, LINDSAY E.

Inventor name: LOW, PHILIP S.

Inventor name: KULARATNE, SUMITH A.

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602013062132

Country of ref document: DE

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1192943

Country of ref document: AT

Kind code of ref document: T

Effective date: 20191115

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200224

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191023

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191023

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200124

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200123

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191023

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191023

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191023

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200123

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191023

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191023

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200224

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2765896

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20200611

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191023

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602013062132

Country of ref document: DE

PG2D Information on lapse in contracting state deleted

Ref country code: IS

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191023

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191023

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191023

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191023

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200223

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1192943

Country of ref document: AT

Kind code of ref document: T

Effective date: 20191023

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20191231

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191023

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191023

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191023

26N No opposition filed

Effective date: 20200724

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20191219

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191023

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191023

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20191231

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191023

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20131219

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191023

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191023

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191023

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230527

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20231124

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20231221

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20231211

Year of fee payment: 11

Ref country code: IE

Payment date: 20231120

Year of fee payment: 11

Ref country code: FR

Payment date: 20231116

Year of fee payment: 11

Ref country code: DE

Payment date: 20231208

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20240108

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20240102

Year of fee payment: 11